The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd® yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market. At the same time a research article about the study was published on the homepage of the medical journal The Lancet entitled "Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial". The study did not reach the primary efficacy endpoint of preserving endogenous insulin production, as measured by meal-stimulated C-peptide, in patients treated with Diamyd® compared to placebo. There was no statistically significant difference in hemoglobin A1c (HbA1c) or mean daily insulin dose between the groups receiving Diamyd® and the placebo treated group.
The Phase II study conducted by Type 1 Diabetes TrialNet is a multicenter, randomized, double-blind study that recruited 145 patients, 3 to 45 years old, in the United States and Canada. The patients, diagnosed with type 1 diabetes within three months of entering the study, were divided into three equal groups of which one group received three injections of Diamyd® (day 1, 30 and 90), one group received two injections of Diamyd® and one injection of placebo, and one group received three injections of placebo. All of the patients had some endogenous insulin production left and were GAD-antibody positive at entering the study. The patients have been followed for 12 months and will be followed for another 12 months. Diamyd® was well tolerated, as demonstrated by a similar number of adverse events reported in the groups treated with Diamyd® and in the placebo group.
"The outcome in this North American study was unfortunately not better than in our larger European Phase III study," says Peter Zerhouni, Acting President and CEO of Diamyd. "However, TrialNet concluded in its presentation that Diamyd® and the active substance GAD65 may have an effect when given earlier in the disease process to prevent type 1 diabetes, in a different treatment regimen, or in combination with other drugs."
On May 9, 2011, Diamyd Medical announced that a European Phase III study with Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal-stimulated C-peptide, although a small positive effect was seen. Furthermore, Diamyd® was well tolerated as demonstrated by a similar number of adverse events in the Diamyd® treated groups compared to the placebo treated group. The follow-up period of the European Phase III study was closed on June 1, 2011. Detailed results of the European study will be presented later today, June 28, at the diabetes conference ADA in San Diego.
On June 23, Diamyd announced that the Company decided to initiate closure of the parallel US Phase III study DiaPrevent, based on a blinded analysis of efficacy data collected to date in the study, and the data from the European Phase III study.
An externally funded and researcher-initiated Phase II study with Diamyd® is being conducted, aiming to prevent type 1 diabetes in children at high risk of developing the disease. That study is not affected by the findings in the other studies with Diamyd®.
Metabolomic biomarkers improve diabetes risk prediction accuracy